Werewolf Therapeutics, Inc.HOWLNASDAQ
Loading
R&D Expenses Over TimeStrong
Percentile Rank67
3Y CAGR-0.1%
5Y CAGR+26.4%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
-0.1%/yr
Annual compound
5Y CAGR
+26.4%/yr
Recent deceleration
Percentile
P67
Within normal range
vs 5Y Ago
3.2x
Strong expansion
Streak
1 yr
Consecutive declineStrong
PeriodValueYoY Change
TTM$53.62M-5.0%
2024$56.43M+35.1%
2023$41.78M-22.3%
2022$53.76M+52.4%
2021$35.27M+111.9%
2020$16.64M+162.5%
2019$6.34M-